General
Preferred name
CONIVAPTAN
Synonyms
CONIVAPTAN HYDROCHLORIDE ()
YM087 ()
Vaprisol ()
Conivaptan HCl ()
YM 087 ()
Conivaptan (hydrochloride) ()
CI-1025 ()
YM-087 ()
Conivaptan-d4 ()
P&D ID
PD009673
CAS
168626-94-6
210101-16-9
1129433-63-1
Tags
available
drug
Approved by
FDA
First approval
2005
Drug indication
Hyponatremia
Cardiovascular disease
Euvolemic hyponatremia
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Conivaptan (hydrochloride) is a non-peptide antagonist of vasopressin receptor, with Ki values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively.
PRICE 62
DESCRIPTION Conivaptan is a non-peptide vasopressin receptor antagonist. It antagonises the V1A and V2 receptors but does not inhibit V1B receptor activity. (GtoPdb)
DESCRIPTION Conivaptan hydrochloride (Vaprisol) is an orally active vasopressin V2 and V1A receptor antagonist, used in the therapy of hypervolemic hyponatremia and euvolemic. (TargetMol Bioactive Compound Library)
DESCRIPTION Positive allosteric modulator of CB2 receptors; active in vivo (Tocris Bioactive Compound Library)
DESCRIPTION Conivaptan, also called as YM 087 or Vaprisol, is the first is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist) approved by United States Federal Drug Administrations (FDA) for the treatment of hyponatremia. (BOC Sciences Bioactive Compounds)
DESCRIPTION Conivaptan is an antidiuretic hormone inhibitor used to raise serum sodium levels. (Enamine Bioactive Compounds)
Compound Sets
29
BOC Sciences Bioactive Compounds
conivaptan-cas-210101-16-9-item-101892
Cayman Chemical Bioactives
23728
26455
ChEMBL Approved Drugs
CHEMBL1201108
CHEMBL1755
ChEMBL Drugs
CHEMBL1201108
CHEMBL1755
Concise Guide to Pharmacology 2017/18
2203
Concise Guide to Pharmacology 2019/20
2203
Concise Guide to Pharmacology 2021/22
2203
Concise Guide to Pharmacology 2023/24
2203
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00872
DrugBank Approved Drugs
DB00872
DrugCentral
732
DrugCentral Approved Drugs
732
DrugMAP
DM1V329
DrugMAP Approved Drugs
DM1V329
DrugMatrix
Enamine Bioactive Compounds
EBC-27237
EU-OPENSCREEN Bioactive Compound Library
EOS101662
Guide to Pharmacology
2203
JUMP-Target 1 Compound Set
151171
Ki Database
YM087
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1755
MedChem Express Bioactive Compound Library
HY-18347A
NCATS Inxight Approved Drugs
0NJ98Y462X
ReFrame library
Selleckchem Bioactive Compound Library
conivaptan-hcl-vaprisol
TargetMol Bioactive Compound Library
T6453
Tocris Bioactive Compound Library
6830
External IDs
66
Properties
(calculated by RDKit )
Molecular Weight
498.21
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
6
Aromatic Ring Count
5
cLogP
6.51
TPSA
78.09
Fraction CSP3
0.09
Chiral centers
0.0
Largest ring
7.0
QED
0.3
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Vasopressin Receptor
vasopressin receptor 1a
Vasopressin receptor 2
AVPR1A, AVPR2
AVPR1A
Primary Target
Vasopressin Receptors
MOA
Antagonist
Vasopressin Receptor antagonist
Indication
hyponatremia
Pathway
GPCR/G protein
Source data